General
Preferred name
QUETIAPINE
Synonyms
QUETIAPINE FUMARATE ()
Quetiapine hemifumarate ()
Quetiapine (D4 fumarate) ()
Quetiapine (fumarate) ()
ICI-204636 ()
Seroquel ()
Quetiapine (hemifumarate) ()
ICI204636 ()
Quetiapine (ICI-204636) fumarate ()
ICI-204636 fumarate ()
ZD-5077 ()
ZM-204636 ()
Seroquel Xr ()
NSC-758918 ()
Atrolak XL ()
Norsic ()
Seroquel XL ()
Psyquet XL ()
Sondate XL ()
Quetiapine extended release ()
Ebesque XL ()
Zaluron XL ()
Seotiapim XL ()
Tenprolide XL ()
Brancico XL ()
Mintreleq XL ()
Biquelle XL ()
FK-947E ()
ICI 204,636 ()
ZD5077 ()
FK947E ()
Utapine ()
ZM 204,636 ()
Quetiapine (as fumarate) ()
Quetiapine (hemifumarate) (CRM) ()
Quetiapine-d8 (fumarate) ()
P&D ID
PD009953
CAS
111974-72-2
111974-69-7
1185247-12-4
Tags
natural product
drug
available
Approved by
FDA
First approval
1997
Drug Status
approved
Drug indication
Alcohol dependence
Antipsychotic
Schizophrenia
Max Phase
Phase 4
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
METABOLISM Hepatic. The major metabolic pathways are sulfoxidation, mediated by cytochrome P450 3A4 (CYP3A4), and oxidation of the terminal alcohol to a carboxylic acid. The major sulfoxide metabolite of quetiapine is inactive. Quetiapine also undergoes hydroxylation of the dibenzothiazepine ring, O-deakylation, N-dealkylation, and phase II conjugation. The 7-hydroxy and 7-hydroxy-; N-delakylated metabolites appear to be active, but are present in very low concentrations.
DESCRIPTION Quetiapine displays affinity for numerous receptors from the dopamine, serotonin and adrenergic families, in addition to the histamine H1 receptor. The anti-psychotic properties of the drug are believed to result from its antagonism of dopamine D2 and 5-HT2A receptors.
Marketed formulations may contain quetiapine fumarate (PubChem CID 5281025) or quetiapine hemifumarate (PubChem CID 73013330). (GtoPdb)
DESCRIPTION Potent and selective sphingosine-1-phosphate receptor 1 (S1P1) agonist (Tocris Bioactive Compound Library)
DESCRIPTION 5-HT2/D2 antagonist; atypical antipsychotic (Tocriscreen Plus)
Compound Sets
37
AdooQ Bioactive Compound Library
A10767
Axon Medchem Screening Library
1354
Cayman Chemical Bioactives
14152
22603
23981
32946
ChEMBL Approved Drugs
CHEMBL3188993
CHEMBL716
ChEMBL Drugs
CHEMBL3188993
CHEMBL716
Concise Guide to Pharmacology 2019/20
50
Concise Guide to Pharmacology 2021/22
50
Concise Guide to Pharmacology 2023/24
50
Drug Repurposing Hub
DrugBank
DB01224
DrugBank Approved Drugs
DB01224
DrugCentral
2337
DrugCentral Approved Drugs
2337
DrugMAP
DM1N62C
DrugMAP Approved Drugs
DM1N62C
DrugMatrix
Enamine BioReference Compounds
EU-OPENSCREEN Bioactive Compound Library
EOS102173
Guide to Pharmacology
50
Ki Database
Quetiapine
LSP-MoA library (Laboratory of Systems Pharmacology)
CHEMBL716
Mcule NIBR MoA Box Subset
MCULE-1498636422
MedChem Express Bioactive Compound Library
HY-14544
HY-B0031
Natural product-based probes and drugs
NCATS Inxight Approved Drugs
BGL0JSY5SI
NIH Clinical Collections (NCC)
Novartis Chemogenetic Library (NIBR MoA Box)
NPC Screening Collection
Other bioactive compounds
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
Quetiapine-fumarate(Seroquel)
quetiapine
TargetMol Bioactive Compound Library
T6241
The Spectrum Collection
Tocris Bioactive Compound Library
4735
Tocriscreen Plus
4735
VGSC-DB
NA0058
External IDs
84
Properties
(calculated by RDKit )
Molecular Weight
383.17
Hydrogen Bond Acceptors
6
Hydrogen Bond Donors
1
Rotatable Bonds
5
Ring Count
4
Aromatic Ring Count
2
cLogP
2.86
TPSA
48.3
Fraction CSP3
0.38
Chiral centers
0.0
Largest ring
7.0
QED
0.8
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target Type
7-TM Receptors
Target
Dopamine Receptor
5-HT Receptor
HT
Adrenergic Receptor
dopamine
ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD1, DRD2, DRD3, DRD4, DRD5, HRH1, HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2C, HTR3A, HTR6, HTR7, SLC6A2
Atypical antipsychotic
5-HT Receptor,Dopamine Receptor
Pathway
GPCR/G protein
Neuronal Signaling
Neuroscience
Primary Target
Non-selective 5-HT2
MOA
Antagonist
alpha1-Adrenoceptor Antagonists
dopamine receptor antagonist, serotonin receptor antagonist
Member status
virtual
Indication
schizophrenia, bipolar disorder
Therapeutic Indication
Neuroleptic
Therapeutic Class
CNS & PNS
Antipsychotic Agents
VGSC Target
Nav1.5
Source data